Heron Therapeutics Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/16/2026)
| Balance Sheet | Total Assets | 255,877,000.00 | ROE | 5.60 % |
| Balance Sheet | Total Equity | 14,333,000.00 | ROA | -7.89 % |
| Cashflow | Capital Expenditures | -317,000.00 | P/FCF | -2.16 |
| Cashflow | Free Cash Flow | -27,908,000.00 | – | – |
| Cashflow | Operating Cash Flow | -27,591,000.00 | P/CF | -2.19 |
| Income | Earnings per Share (diluted) | -0.12 | Div. Yield | – |
| Income | Net Income | -20,195,000.00 | P/E | -3.02 |
| Income | Shares Outstanding | 166,707,000.00 | P/B | 4.21 |
| Income | Total Revenue | 154,904,000.00 | P/S | 0.39 |
Ratios calculated on: 10/14/2026
Company Description
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.appharma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more